• News

"New Ocular Health Supplement Targets Glaucoma" - Nancy Hemphill

  • Healio: Primary Care Optometry News
  • New York, NY
  • (July 10, 2019)

Guardion Health Sciences Inc. announced the launch of GlaucoCetin, a propriety formula shown in a clinical trial to reverse mitochondrial dysfunction in the optic nerve cells of glaucoma patients. GlaucoCetin is an enhanced version of the parent compound, GlaucoHealth, which was created by Robert Ritch, MD, clinical professor of ophthalmology at the Icahn School of Medicine at Mount Sinai. According to Dr. Ritch, “Formulations with IOP-independent neuroprotective effects could be additive in slowing progression rates by reversing mitochondrial dysfunction.” He added, “Stabilizing mitochondria could shift the treatment paradigm to an earlier stage of disease, prior to retinal ganglion cell death.”

— Robert Ritch, MD, Clinical Professor, Ophthalmology, Icahn School of Medicine at Mount Sinai, Chief, Glaucoma Services, New York Eye and Ear Infirmary of Mount Sinai

Learn more